Both in Pharmaceuticals
Atrium Therapeutics vs Cue Biopharma
Over the past year RNA returned −88.2% and CUE returned −3.0%; their daily moves had a correlation of 0.02.
RNA −88.2% CUE −3.0%Growth of $1, one year, split-adjusted
| Metric | RNA | CUE |
|---|---|---|
| Price | $8.27 | $20.87 |
| Market cap | $141.5M | $151.6M |
| Today | +0.12% | −2.70% |
| 1 month | +1.6% | −17.3% |
| 6 months | −38.4% | −31.4% |
| Year to date | −88.5% | +127.8% |
| 1 year | — | +0.8% |
| Revenue growth (YoY) | −21.9% | +166.7% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −672.0% | −1943.2% |
| P/E (TTM) | — | — |
| Price / sales | 3.9× | 4.0× |
| Net cash | $263.9M | $16.4M |
| Dividend yield | — | — |
| Volatility (60d) | 65.3% | 137.1% |
| Short % of float | 22.9% | 12.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).